Education
About Us
Working with TipRanks
Follow Us
Standard BioTools (LAB)
NASDAQ:LAB
LAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.99 - $3.04
Previous CloseN/A
Volume335.74K
Average Volume (3M)2.20M
Market Cap
$394.59M
Enterprise Value$440.21M
Total Cash (Recent Filing)$95.40M
Total Debt (Recent Filing)$172.06M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
May 07, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding372,258,800
10 Day Avg. Volume3,062,010
30 Day Avg. Volume2,204,028
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.53
Price to Cash Flow (P/CF)-3.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.73
Enterprise Value/Ebitda-3.78
Forecast
1Y Price Target
$2.50Price Target Upside108.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Standard BioTools News
PremiumCompany Announcements
Standard BioTools Inc. Faces Revenue Decline Amid Market Challenges
PremiumCompany Announcements
Standard BioTools Reports 2024 Financial Results
PremiumCompany Announcements
Standard BioTools Reports 2024 Financial Results and Strategic Outlook
---
Bulls Say, Bears Say
Bulls Say
Operational ImprovementsDespite headwinds, LAB management continues to make progress on underlying operations and is targeting improvements.
Strategic InitiativesThe merger with SLGC nearly doubles LAB's revenues, expands the TAM & strengthens the balance sheet.
Bears Say
Financial GuidanceFY25 guidance was disappointing at $165M-$175M vs. consensus of $186.9M or a -3% decline at the midpoint.
Revenue Miss2Q revenue missed consensus ($37.2M < $48.2M), a notable miss after a solid 1Q where management reiterated FY'24 guidance.
---
Ownership Overview
38.61% Insiders
8.50% Mutual Funds
0.15% Other Institutional Investors
42.76% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LAB FAQ
What was Standard BioTools’s price range in the past 12 months?
Standard BioTools lowest stock price was $0.99 and its highest was $3.04 in the past 12 months.
What is Standard BioTools’s market cap?
Standard BioTools’s market cap is $394.59M.
When is Standard BioTools’s upcoming earnings report date?
Standard BioTools’s upcoming earnings report date is May 07, 2025 which is in 61 days.
How were Standard BioTools’s earnings last quarter?
Standard BioTools released its earnings results on Feb 26, 2025. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.057 by -$0.033.
Is Standard BioTools overvalued?
According to Wall Street analysts Standard BioTools’s price is currently Undervalued.
Does Standard BioTools pay dividends?
Standard BioTools does not currently pay dividends.
What is Standard BioTools’s EPS estimate?
Standard BioTools’s EPS estimate is -0.06.
How many shares outstanding does Standard BioTools have?
Standard BioTools has 372,258,800 shares outstanding.
What happened to Standard BioTools’s price movement after its last earnings report?
Standard BioTools reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.057. Following the earnings report the stock price went down -11.111%.
Which hedge fund is a major shareholder of Standard BioTools?
Currently, no hedge funds are holding shares in LAB
---
Standard BioTools Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.50 (108.33% Upside)
$2.50 (108.33% Upside)
Blogger Sentiment
Bullish
LAB Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 7.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $5.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 19.8%
Last 30 Days ▲ 19.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.48%
12-Months-Change
Fundamentals
Return on Equity
-43.75%
Trailing 12-Months
Asset Growth
89.54%
Trailing 12-Months
Company Description
Standard BioTools
Fluidigm Corp. is engaged in the development, manufacture and marketing of biotechnology tools fro life sciences research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics; and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen R. Quake and Gajus V. Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.
---
LAB Company Deck
---
LAB Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Despite the successful realization of cost synergies and a strong balance sheet, the company faced significant revenue declines and market challenges, including reduced instrument sales and potential impacts from NIH funding and tariffs. The growth in consumables and strategic initiatives in proteomics provide optimism, but the current market and economic environment pose challenges.Read More>---
LAB Stock 12 Month Forecast
Average Price Target
$2.50
▲(108.33% Upside)
Technical Analysis
Best Analysts Covering LAB
1 Year
1 Year Success Rate
1/9 ratings generated profit
1 Year Average Return
-30.67%
reiterated a buy rating 9 days ago
Copying Daniel Brennan's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -30.67% per trade.
---